Synonym
Grepafloxacin Hydrochloride; OPC-17116; DSSTox_CID_26692; DSSTox_RID_81826; DSSTox_GSID_46692; grepafloxacin hydrochloride; OPC 17116; OPC-17116; Raxar;
IUPAC/Chemical Name
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride
InChi Key
IEPMBYOIQGCVHO-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H22FN3O3.ClH/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12;/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26);1H
SMILES Code
CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO, not in water |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
395.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Watanabe M, Kobayashi M, Ogura J, Takahashi N, Yamaguchi H, Iseki K. Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats. J Pharm Pharm Sci. 2014;17(1):25-33. PubMed PMID: 24735760.
2: Gontijo AV, Brillault J, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S.
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1.
Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrob Agents Chemother. 2014
Jul;58(7):3942-9. doi: 10.1128/AAC.02818-14. Epub 2014 May 5. PubMed PMID:
24798283; PubMed Central PMCID: PMC4068515.
3: Atkins HS, Spencer S, Brew SD, Jenner DC, Sefton AM, MacMillan AP, Brooks TJ, Simpson AJ. Evaluation of azithromycin, trovafloxacin and grepafloxacin as
prophylaxis against experimental murine Brucella melitensis infection. Int J
Antimicrob Agents. 2010 Jul;36(1):66-8. doi: 10.1016/j.ijantimicag.2009.10.003.
Epub 2009 Dec 21. PubMed PMID: 20022474.
